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Abstract
Background: Antiretroviral therapy for HIV-2 infection is hampered by intrinsic resistance to many of the drugs used to treat
HIV-1. Limited studies suggest that the integrase inhibitors (INIs) raltegravir and elvitegravir have potent activity against HIV-
2 in culture and in infected patients. There is a paucity of data on genotypic variation in HIV-2 integrase that might confer
intrinsic or transmitted INI resistance.
Methods: We PCR amplified and analyzed 122 HIV-2 integrase consensus sequences from 39 HIV-2–infected, INI-naive
adults in Senegal, West Africa. We assessed genetic variation and canonical mutations known to confer INI-resistance in
HIV-1.
Results: No amino acid-altering mutations were detected at sites known to be pivotal for INI resistance in HIV-1 (integrase
positions 143, 148 and 155). Polymorphisms at several other HIV-1 INI resistance-associated sites were detected at positions
72, 95, 125, 154, 165, 201, 203, and 263 of the HIV-2 integrase protein.
Conclusion: Emerging genotypic and phenotypic data suggest that HIV-2 is susceptible to the new class of HIV integrase
inhibitors. We hypothesize that intrinsic HIV-2 integrase variation at ‘‘secondary’’ HIV-1 INI-resistance sites may affect the
genetic barrier to HIV-2 INI resistance. Further studies will be needed to assess INI efficacy as part of combination
antiretroviral therapy in HIV-2–infected patients.
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Introduction
HIV-2 is endemic in West Africa and has limited spread to a
number of other locales worldwide [1]. Compared to HIV-1,
HIV-2 infection is characterized by a much longer asymptomatic
stage, lower plasma viral loads, slower decline in CD4 counts,
decreased mortality rate due to AIDS, and lower rates of genital
tract shedding, mother to child transmission, and sexual
transmission [1,2,3,4,5,6,7]. Nonetheless, a significant proportion
of HIV-2–infected individuals eventually progress to AIDS and
may benefit from antiretroviral therapy (ART) [3,8]. Treatment of
HIV-2 infection is complicated by the intrinsic resistance of the
virus to non-nucleoside reverse transcriptase inhibitors (NNRTIs)
and the fusion inhibitor T-20 (enfuvirtide) [9,10]. In addition,
HIV-2 exhibits a low genetic barrier to nucleoside reverse
transcriptase inhibitor (NRTI) resistance and is partially resistant
to several protease inhibitors (PIs) [9,10,11,12,13].
In preliminary studies, the integrase inhibitors (INIs) raltegravir,
elvitegravir and S/GSK1349572 have shown in vitro activity against a
limited number of wild-type HIV-2 strains [14,15,16] and genotypic
surveys from Europe suggest that primary mutations leading to INI
resistance in HIV-1 are rare in HIV-2 sequences from INI-naı ¨ve
individuals [15,17,18]. Anecdotal clinical reports suggest that
raltegravir-containing regimens can initially suppress HIV-2 plasma
RNA loads and may therefore be useful for treating HIV-2 infection
[19,20,21,22,23,24,25]. However, the long-term therapeutic benefits
of raltegravir and other INIs will likely be compromised by emergent
drug resistance, as evidenced by the appearance of resistance-
associated mutations in sequences from raltegravir-treated HIV-2
patients [19,20,21,22,23,24,25]. Although a small sampling of
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characterized, the effects of specific amino acid changes in HIV-2
integrase on INI susceptibility are largely unknown and may
potentially be modulated by other naturally-occurring amino acids
in the HIV-2 integrase protein.
With these issues in mind, we examined the prevalence of INI
resistance-associated mutations in HIV-2 sequences from INI-
naı ¨ve patients in Senegal, West Africa. To our knowledge this is
the first such genotypic survey of potential INI-resistance from
HIV-2 endemic West Africa. Our results suggest that intrinsic INI
resistance is infrequent in West-African HIV-2 isolates, but that
background variation in HIV-2 integrase may accelerate the
development of INI resistance in this patient population.
Methods
Subjects and specimen collection
Patient samples were collected as part of an NIH-sponsored,
ongoing prospective longitudinal cohort study of ART for HIV-2
infection in Senegal, West Africa; enrollment began in October
2005 [26]. HIV-2 infected individuals with clinical AIDS, CD4
counts ,200/mm
3,o r,350/mm
3 with clinical symptoms were
treated with antiretrovirals as part of the Senegalese Government
Antiretroviral program (ISAARV) at the Clinique des Maladies
Infectieuses Ibrahima DIOP Mar, Centre Hospitalier Universi-
taire de Fann, Universite Cheikh Anta Diop de Dakar, Dakar,
Senegal. HIV-2–infected subjects initiating ART (and those
already on ART) in the ISAARV program were referred to
participate in this study.
Subjects were screened for HIV-1 and HIV-2 by serologic
testing. Serum samples were tested for HIV seropositivity using a
microwell plate HIV-1/HIV-2 enzyme immunoassay (Genetic
Systems) or Genscreen HIV-1/2 (BioRad) or by a rapid HIV test
(Determine; Inverness Medical). HIV-2 seropositivity was con-
firmed using a rapid synthetic peptide-based membrane immu-
noassay (Multispot; Sanofi Pasteur) or the ImmunoComb II HIV-
1 & 2 BiSpot assay (Orgenics), both of which distinguish HIV-1,
HIV-2 and dual HIV-1/HIV-2 seropositivity. At enrollment and
subsequent follow-up visits (at 1 month and then every 4 months),
subjects underwent a physical examination and completed an
interview with questions concerning demographic characteristics
and sexual and other behaviors. A routine medical history and
exam was performed and recorded on a standardized form by
study clinicians. Peripheral blood was collected into tubes
containing ethylenediaminetetraacetic acid (EDTA) and analyzed
using a FACSCount analyzer (Becton Dickinson Biosciences, San
Jose, CA) to determine the number of CD4, CD8 and CD3 cells/
mm
3. Samples were also subjected to HIV-2 quantitative RNA
viral load assays as previously described [27].
HIV-2 Integrase genotyping
Purified PBMC DNA was extracted from each patient sample
using the QIAamp DNA Blood Mini Kit (Qiagen Inc., Valencia,
CA) and quantified by spectrophometry (Nanodrop, Wilmington,
DE). HIV-2–specific nested PCR [26,27] was used to amplify
the integrase-encoding region of pol (nucleotides 4738 to 5777,
numbered as per HIV-2ROD, GenBank accession # M15390).
Briefly, PCR was performed using 0.1–0.25 micrograms of PBMC
DNA per reaction. Nested primers for PCR amplification were as
follows: first round forward, H2AB_INT F1 (AAR GAA GCA
RTM TAT GTW GSA TGG GTS CCA GC); first round reverse,
H2AB_INT R1 (GGA CAA TAW CTT TTC YCC YCT GAT
GGC TCT YCT TAC TTC); second round forward, H2AB_INT
F2 (CAG GAA GTA GAY CAY TTA GTR AGT CAR GG);
second round reverse, H2AB_INT R2 (GGG AAT ATT ACY
CTR CTG CAA GTC CAC C). Reaction conditions and thermal
cycling parameters were as previously described [26,27].
All PCR amplifications were performed using procedural
safeguards to prevent contamination including aliquoting of all
reagents and physical separation of sample processing and post-PCR
handling steps. In addition, negative control reactions that lacked
template DNA were included in every PCR experiment, and
reactions containing 10 genome equivalents of HIV-2 DNA
(pROD10) were used to monitor PCR amplification efficiency. Bulk
PCR products were agarose gel-purified (S.N.A.P. UV-Free Gel
Purification Kit, Invitrogen) and sequenced via standard dideoxy-
chain termination methods using primers H2AB_INT_seqR
(AAATTCATGCAATGAACTGCC), H2AB_INT_seqF (TAGTA-
GAAGCAATGAATCACC), H2AB_INT F2 and H2AB_INT R2
(see above). Genbank Accession numbers of the HIV-2 sequences
from this study: JF811132-JF811253.
Phylogenetic analyses and resistance-associated
genotyping
All patient-derived sequences were assessed for potential sample
mix-up and contamination as recommended by the Division of
AIDS, National Institute of Allergy and Infectious Diseases,
National Institutes of Health (http://www.hiv.lanl.gov/content/
sequence/TUTORIALS/CONTAM/contam_main.html). HIV-
2 patient sequences were aligned with reference sequences from
the Los Alamos National Laboratory HIV Database (http://hiv-
web.lanl.gov) using Muscle (http://www.ebi.ac.uk/Tools/msa/
muscle) followed by manual adjustment using MacClade (version
4.08). Neighbor-joining and maximum likelihood methods were
used to estimate phylogenetic trees with PAUP* (v4.0 b10)
and DIVEIN (http://indra.mullins.microbiol.washington.edu/
DIVEIN). HIV-2 sequences were assigned to groups (‘‘subtypes’’)
based on these phylogenetic analyses. In addition, the integrase-
encoding region of each patient sequence was translated in
MacClade (version 4.08), and amino acid variation was assessed at
sites associated with INI resistance in HIV-1. The list of integrase
sites analyzed in our study was compiled from the Stanford HIV
Drug Resistance Database (http://hivdb.stanford.edu/cgi-bin/
INIResiNote.cgi) and the International AIDS Society-USA
Update of Drug Resistance Mutations in HIV-1 (December
2010; http://www.iasusa.org/resistance_mutations/mutations_
figures.pdf).
Ethics Statement
This study was conducted according to procedures approved by
the Institutional Review Boards of the Universities of Washington
and Dakar, and the Senegalese National AIDS Committee-
Ministry of Health. All subjects provided written informed consent
for study participation.
Results
We analyzed HIV-2 integrase sequences from 39 Senegalese
adults whose baseline characteristics are shown in Table 1. All
individuals were INI-naı ¨ve; 6 were ART-naı ¨ve, and 33 patients
were receiving NRTI+PI–based regimens at the time of integrase
genotyping (median time on ART: 711 days, range: 90–2642
days). Median HIV-2 plasma viral loads and CD4 counts at time
of sampling were 2.76 log10 copies/ml and 225 cells/mm
3,
respectively. A total of 122 HIV-2 patient-derived consensus
(‘‘bulk’’) sequences were obtained, with longitudinal sequences
from 24 (62%) individuals. Of the 39 patients in our study, 37 were
infected with group A HIV-2, and two were infected with group B
HIV-2 Integrase Genotypes
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(intra- or inter-group) were detected (Figure 1).
To assess the potential for intrinsic INI resistance in our HIV-2
cohort, we determined the amino acid sequence encoded by each
patient-derived PCR product and examined the specific residues
present at each of 35 individual INI resistance-associated sites in the
integrase protein (Figure 2). Importantly, at the three positions
known to be pivotal for INI resistance in HIV-1 (143, 148 and 155),
all of the Senegalese HIV-2 sequences were identical to the
consensus HIV-1 genotype(i.e., no amino acid differencesrelative to
the HIV-1 consensus sequence were observed at these sites).
However, we observed a large number of differences between HIV-
1 and HIV-2 at other sites implicated in INIresistance. Amino acids
corresponding to resistance-associated changes in HIV-1 were
detected at positions 72I, 95K, 125K, 154I, 165I, 201I, 203M, and
263K of the HIV-2 integrase protein (Figure 2, yellow boxes). The
most common resistance-assocated residues were 72I, 165I, 201I
and 203M (Figure 2, bottom). Taken together, these findings
demonstrate that HIV-2 sequences from INI-naı ¨ve patients in
Senegal frequently encode amino acids that correspond to
‘‘secondary’’ resistance-associated changes in HIV-1.
Discussion
In our current study of HIV-2 integrase-encoding sequences
from INI-naı ¨ve patients in Senegal, we found no evidence of the
primary mutations responsible for raltegravir or elvitegravir
resistance in HIV-1. Although we cannot rule out the possibility
that Y143R/C, Q148H/R/K or N155H variants exist at low
frequencies in HIV-2 patients, our data indicate that such mutants
are rarely present as the majority genotype in INI-naı ¨ve
individuals from the Senegal cohort. In contrast, we identified
several naturally-occurring amino acids in HIV-2 integrase that
are equivalent to secondary raltegravir or elvitegravir resistance-
associated replacements in HIV-1. These data raise the possibility
that HIV-2 variants containing primary INI resistance mutations
Figure 1. Phylogenetic tree of HIV-2 integrase nucleotide sequences (N=122, black taxa) from 39 INI-naı ¨ve Senegalese adults and
HIV-2 reference sequences (gray taxa) from the Los Alamos HIV Database (http://www.hiv.lanl.gov). HIV-2 Group A (N=37 subjects) and
Group B (N=2 subjects) clades are shown.
doi:10.1371/journal.pone.0022204.g001
Table 1. Baseline characteristics of HIV-2 infected Patients.
N= =39
Females (%) 28 (72%)
Age (median, range) 48 (22, 61)
WHO Stage
1 6 (15%)
2 8 (21%)
3 18 (46%)
4 7 (18%)
Baseline CD4 count (cells/mm
3; Median, Range) 225 (6, 819)
Baseline HIV-2 Plasma RNA
Median (log10 copies/mL)
(Range, % undetectable (,25 copies/mL))
2.76 (1.63, 4.12, 38%)
doi:10.1371/journal.pone.0022204.t001
HIV-2 Integrase Genotypes
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replication fitness relative to their HIV-1 counterparts. Accord-
ingly, the genetic barrier to raltegravir or elvitegravir resistance
may be lower in HIV-2 relative to HIV-1, as shown in recent
studies of NRTI-resistant viruses [13,28]. Additional culture-based
studies of patient-derived strains and site-directed mutants of HIV-
2 integrase are required to address this issue.
Our analysis of West African patients, together with previous
studies ofHIV-2–infected individuals residinginEurope [15,17,18],
provides encouraging information suggesting that intrinsic or
transmitted INI-resistance in HIV-2 is rare at the present time.
However, studies of a limited number of raltegravir-treated patients
suggest that INI resistance is likely to be a growing clinical problem
in HIV-2, and that the canonical INI-resistance pathways defined
by replacements Y143R/C, Q148H/R/K and N155H in HIV-1
integrase may play similar roles in HIV-2 [19,20,21,22,23,25]. In
this regard, the recent development of novel strand transfer
inhibitors with improved activity against INI-resistant mutants of
HIV-1 [29,30] may lead to favorable treatment options for HIV-2
patients harboring raltegravir- or elvitegravir-resistant viruses.
Because HIV-2 is intrinsically resistant to many of the
antiretroviral drugs used to treat HIV-1, the emerging data on
HIV-2 integrase variation and INI sensitivity potentially provide a
new avenue for effective HIV-2 treatment. Ultimately, however,
only appropriately designed randomized trials of specific antiret-
roviral regimens will provide the information patients and
clinicians need to improve HIV-2 treatment [31,32].
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